Amey Chalke

I have first question on the specialty medicines. There's seems to be some deceleration of growth in this segment. Is it possible for the management to give color on reasons for slower growth in 1Q?

Sure. But any product in this quarter, particularly where you saw some impact, which could have affected the growth this quarter?

Sure. That's helpful. Second question I have on semaglutide. It is quite visible that sema could become a meaningful revenue driver for us, both in India and ROW. In light of this, I just wanted to understand our preparedness of the supply chain. How much supply we have been able to secure in terms of sense for the full year of FY27?